吉非替尼治疗EGFR基因突变肺腺癌的疗效观察  

Efficacy of gefitinib in the treatment of lung adenocarcinoma with EGFR gene mutation

作　　者：陈晓文 CHEN Xiao-wen(Eighth Department of Internal Medicine,Fengcheng Central Hospital,Fengcheng 118100,China)

机构地区：[1]辽宁省凤城市中心医院内八科,118100

出　　处：《中国现代药物应用》2021年第14期127-129,共3页Chinese Journal of Modern Drug Application

摘　　要：目的观察吉非替尼治疗表皮生长因子受体(EGFR)基因突变肺腺癌的临床效果。方法54例EGFR基因突变肺腺癌患者,随机分为观察组和对照组,每组27例。观察组患者采用吉非替尼治疗,对照组患者采用安罗替尼治疗。比较两组患者的治疗效果,不良反应发生率。结果观察组患者的病情控制率为92.59%,明显高于对照组的62.96%,差异有统计学意义(P<0.05)。观察组的不良反应发生率为18.52%,与对照组的14.81%比较,差异无统计学意义(P>0.05)。结论EGFR基因突变肺腺癌患者采用吉非替尼治疗的效果优于安罗替尼,具有较好的治疗安全性,值得推荐。Objective To investigate the clinical efficacy of gefitinib in the treatment of lung adenocarcinoma with epidermal growth factor receptor(EGFR)gene mutation.Methods 54 case of lung adenocarcinoma with EGFR gene mutation were randomly divided into an observation group and a control group,with 27 patients in each group.Patients in the observation group were treated with gefitinib,while patients in the control group were treated with arotinib.The clinical efficacy and the incidence of adverse reactions were compared between these two groups.Results The disease control rate of the observation group was 92.59%,which was significantly higher than 62.96%of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions of the observation group was 18.52%,while that of the control group was 14.81%,the difference was not statistically significant(P>0.05).Conclusion The clinical efficacy of gefitinib in the treatment of patients with lung adenocarcinoma with EGFR gene mutation is better than that of anlotinib,with a higher safety.Thus,it is worth promoting.

关 键 词：吉非替尼 安罗替尼 表皮生长因子受体 基因突变 肺腺癌 病情控制率 

分 类 号：R734.2[医药卫生—肿瘤]